153 related articles for article (PubMed ID: 37417528)
1. Should we abandon hormonal therapy in endometrial cancer? Outcomes of recurrent and metastatic endometrial cancer treated with systemic progestins.
Kulkarni A; Wright NMA; Forget AN; Ramsay T; Mallick R; Weberpals JI
Cancer Med; 2023 Aug; 12(15):16173-16180. PubMed ID: 37417528
[TBL] [Abstract][Full Text] [Related]
2. Hormonal therapy for women with stage IA endometrial cancer of all grades.
Park JY; Kim DY; Kim TJ; Kim JW; Kim JH; Kim YM; Kim YT; Bae DS; Nam JH
Obstet Gynecol; 2013 Jul; 122(1):7-14. PubMed ID: 23743459
[TBL] [Abstract][Full Text] [Related]
3. Progestin as an alternative treatment option for multi-treated recurrent triple-negative breast cancer.
Xiangying M; Shikai W; Zefei J; Bing S; Yan M; Xin Z; Lijuan D; Yue W; Tao W; Shaohua Z; Santai S
Swiss Med Wkly; 2013; 143():w13765. PubMed ID: 23740185
[TBL] [Abstract][Full Text] [Related]
4. Progestin re-treatment in patients with recurrent endometrial adenocarcinoma after successful fertility-sparing management using progestin.
Park JY; Lee SH; Seong SJ; Kim DY; Kim TJ; Kim JW; Kim JH; Kim YM; Kim YT; Bae DS; Nam JH
Gynecol Oncol; 2013 Apr; 129(1):7-11. PubMed ID: 23283299
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of prognostic factors and comparison of systemic treatment modalities in patients with recurrent or metastatic endometrial carcinoma.
Karagol H; Saip P; Uygun K; Kucucuk S; Aydiner A; Topuz E
Med Oncol; 2006; 23(4):543-8. PubMed ID: 17303913
[TBL] [Abstract][Full Text] [Related]
6. Conservative treatment with progestin and pregnancy outcomes in endometrial cancer.
Hahn HS; Yoon SG; Hong JS; Hong SR; Park SJ; Lim JY; Kwon YS; Lee IH; Lim KT; Lee KH; Shim JU; Mok JE; Kim TJ
Int J Gynecol Cancer; 2009 Aug; 19(6):1068-73. PubMed ID: 19820370
[TBL] [Abstract][Full Text] [Related]
7. Real-world outcomes in patients with advanced endometrial cancer: A retrospective cohort study of US electronic health records.
Monk BJ; Smith G; Lima J; Long GH; Alam N; Nakamura H; Meulendijks D; Ghiorghiu D; Banerjee S
Gynecol Oncol; 2022 Feb; 164(2):325-332. PubMed ID: 34952707
[TBL] [Abstract][Full Text] [Related]
8. A Phase 2, Randomized, Open-Label Study of Irosustat Versus Megestrol Acetate in Advanced Endometrial Cancer.
Pautier P; Vergote I; Joly F; Melichar B; Kutarska E; Hall G; Lisyanskaya A; Reed N; Oaknin A; Ostapenko V; Zvirbule Z; Chetaille E; Geniaux A; Shoaib M; Green JA
Int J Gynecol Cancer; 2017 Feb; 27(2):258-266. PubMed ID: 27870712
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness of high-dose progestin and long-term outcomes in young women with early-stage, well-differentiated endometrioid adenocarcinoma of uterine endometrium.
Park H; Seok JM; Yoon BS; Seong SJ; Kim JY; Shim JY; Park CT
Arch Gynecol Obstet; 2012 Feb; 285(2):473-8. PubMed ID: 21706284
[TBL] [Abstract][Full Text] [Related]
10. Treatment of advanced or recurrent endometrial carcinoma with doxorubicin in patients progressing after paclitaxel/carboplatin: Memorial Sloan-Kettering Cancer Center experience from 1995 to 2009.
Makker V; Hensley ML; Zhou Q; Iasonos A; Aghajanian CA
Int J Gynecol Cancer; 2013 Jun; 23(5):929-34. PubMed ID: 23598889
[TBL] [Abstract][Full Text] [Related]
11. High-dose megestrol acetate in advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study.
Lentz SS; Brady MF; Major FJ; Reid GC; Soper JT
J Clin Oncol; 1996 Feb; 14(2):357-61. PubMed ID: 8636744
[TBL] [Abstract][Full Text] [Related]
12. Fertility-Sparing Approach in Patients with Endometrioid Endometrial Cancer Grade 2 Stage IA (FIGO): A Qualitative Systematic Review.
Giampaolino P; Cafasso V; Boccia D; Ascione M; Mercorio A; Viciglione F; Palumbo M; Serafino P; Buonfantino C; De Angelis MC; Verrazzo P; Grasso G; Gullo G; Bifulco G; Della Corte L
Biomed Res Int; 2022; 2022():4070368. PubMed ID: 36203482
[TBL] [Abstract][Full Text] [Related]
13. Recurrence of prolactin-producing endometrial stromal sarcoma with sex-cord stromal component treated with progestin and aromatase inhibitor.
Leiser AL; Hamid AM; Blanchard R
Gynecol Oncol; 2004 Aug; 94(2):567-71. PubMed ID: 15297205
[TBL] [Abstract][Full Text] [Related]
14. Real-world treatment patterns and clinical outcomes from a retrospective chart review study of patients with recurrent or advanced endometrial cancer who progressed following prior systemic therapy in Europe.
Zhang J; Kelkar SS; Prabhu VS; Qiao Y; Grall V; Miles N; Marth C
BMJ Open; 2024 Apr; 14(4):e079447. PubMed ID: 38569701
[TBL] [Abstract][Full Text] [Related]
15. The role of multi-modality adjuvant chemotherapy and radiation in women with advanced stage endometrial cancer.
Alvarez Secord A; Havrilesky LJ; Bae-Jump V; Chin J; Calingaert B; Bland A; Rutledge TL; Berchuck A; Clarke-Pearson DL; Gehrig PA
Gynecol Oncol; 2007 Nov; 107(2):285-91. PubMed ID: 17688923
[TBL] [Abstract][Full Text] [Related]
16. What is an appropriate second-line regimen for recurrent endometrial cancer? Ancillary analysis of the SGSG012/GOTIC004/Intergroup study.
Nagao S; Nishio S; Okada S; Otsuki T; Fujiwara K; Tanabe H; Takano M; Hasumi Y; Takei Y; Hasegawa T; Matsumoto T; Fujiwara K; Takekuma M; Nakamura K; Shimada M; Suzuki M; Kigawa J
Cancer Chemother Pharmacol; 2015 Aug; 76(2):335-42. PubMed ID: 26092322
[TBL] [Abstract][Full Text] [Related]
17. Hormonal therapy for the management of grade 1 endometrial adenocarcinoma: a literature review.
Ramirez PT; Frumovitz M; Bodurka DC; Sun CC; Levenback C
Gynecol Oncol; 2004 Oct; 95(1):133-8. PubMed ID: 15385122
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the optimal sequence of adjuvant chemotherapy and radiation therapy in the treatment of advanced endometrial cancer.
McEachron J; Zhou N; Spencer C; Shanahan L; Chatterton C; Singhal P; Lee YC
J Gynecol Oncol; 2020 Nov; 31(6):e90. PubMed ID: 33078595
[TBL] [Abstract][Full Text] [Related]
19. Temsirolimus with or without megestrol acetate and tamoxifen for endometrial cancer: a gynecologic oncology group study.
Fleming GF; Filiaci VL; Marzullo B; Zaino RJ; Davidson SA; Pearl M; Makker V; Burke JJ; Zweizig SL; Van Le L; Hanjani P; Downey G; Walker JL; Reyes HD; Leslie KK
Gynecol Oncol; 2014 Mar; 132(3):585-92. PubMed ID: 24456823
[TBL] [Abstract][Full Text] [Related]
20. Risk Factors for Recurrence in Patients with Atypical Endometrial Hyperplasia and Endometrioid Adenocarcinoma after Fertility-Sparing Treatments.
Yin J; Ma S; Shan Y; Wang Y; Li Y; Jin Y; Pan L
Cancer Prev Res (Phila); 2020 Apr; 13(4):403-410. PubMed ID: 32015095
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
